The readmission math nobody runs before buying software
How to size the actual financial opportunity in a readmission reduction initiative before a vendor sizes it for you.
Every vendor will build you an ROI model. You should walk into that meeting with your own, because the difference between the two is the actual negotiation.
Three numbers you already have
Annual admissions. Current 30-day readmission rate. Payer mix. That is enough to get within range, and all three are in your existing reporting.
The number vendors inflate
Relative reduction. Case studies quote 30 to 40 percent. Plan on 10 to 20 for a program you execute well, and treat anything above that as upside rather than as the basis for the business case.
The number nobody computes
What a readmission actually costs you, specifically, given your contracts. Under fee-for-service with an empty bed behind it, a readmission can be revenue-neutral or positive. Under a value-based arrangement it is a direct loss. The same clinical improvement has a different financial value at two buildings in the same portfolio.
Questions from this piece
What is a realistic readmission reduction from a clinical AI tool?
A 10 to 20 percent relative reduction is a defensible planning assumption for a well-executed program. Larger figures appear in vendor case studies but usually reflect a favorable baseline, a concurrent staffing change, or a short measurement window.
Keep reading
What post-acute teams get wrong about clinical AI
Most clinical AI pilots in skilled nursing fail on workflow, not accuracy. What actually determines whether a model changes care.
We build software with AI agents. Humans orchestrate.
How MedPAC actually ships: AI agents do the typing, human staff direct the work, and every change is traceable from prompt to production.